Harvoni is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Gilead Sciences, Inc. The primary component is Ledipasvir; Sofosbuvir.
| Product ID | 61958-1803_6122d2f4-19e4-4aae-89ce-bef7bfc5cb3e |
| NDC | 61958-1803 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Harvoni |
| Generic Name | Ledipasvir And Sofosbuvir |
| Dosage Form | Tablet, Film Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2019-08-28 |
| Marketing Category | NDA / NDA |
| Application Number | NDA205834 |
| Labeler Name | Gilead Sciences, Inc |
| Substance Name | LEDIPASVIR; SOFOSBUVIR |
| Active Ingredient Strength | 45 mg/1; mg/1 |
| Pharm Classes | Hepatitis C Virus NS5A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC],RNA Replicase Inhibitors [MoA],Nucleoside Analog [EXT] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2019-08-28 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA205834 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2019-08-28 |
| Ingredient | Strength |
|---|---|
| LEDIPASVIR | 45 mg/1 |
| SPL SET ID: | f4ec77e4-bae8-4db0-b3d5-bde09c5fa075 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 61958-1801 | Harvoni | LEDIPASVIR and SOFOSBUVIR |
| 61958-1803 | Harvoni | ledipasvir and sofosbuvir |
| 61958-1804 | Harvoni | ledipasvir and sofosbuvir |
| 61958-1805 | Harvoni | ledipasvir and sofosbuvir |
| 72626-2601 | Ledipasvir and Sofosbuvir | Ledipasvir and Sofosbuvir |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() HARVONI 86095994 4608545 Live/Registered |
GILEAD SCIENCES IRELAND UC 2013-10-18 |